1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoidreceptor antagonists with high functional activity.
Clark et al. • 2008 • Bioorg Med Chem Lett. 2008;18(4):1312-7.
© 2024 Corcept Therapeutics, Incorporated
About jeremiah@devisedesigns.com
This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 134 entries already.
Entries by jeremiah@devisedesigns.com
Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study.
Hunt et al. • 2017 • Clin Pharmacol Drug Dev. 2017 Oct 2. doi: 10.1002/cpdd.389.
FKBP5 mRNA expression is a biomarker for GR antagonism.
Bali et al. • 2016 • J Clin Endocrinol Metab. 2016;101(11):4305-4312.
Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.
Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.
Steroid receptors aplenty in prostate cancer.
Sharifi N. • 2014 • N Engl J Med. 2014;370(10):970-1.
“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.
Minireview: nuclear receptors and breast cancer.
Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.
The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT • 1999 • Urol Clin North Am. 1999;26(2):263-73.
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Stringer-Reasor et al. • 2015 • Gynecol Oncol. 2015;138(3):656-62.
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay et al. • 2014 • Horm Cancer. 2014;5(2):72-89.